Evidence map›Paper›PMID 26122846›Full record

ArticleCancer research2015

Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors.

Alexander F Bagley, Ruth Scherz-Shouval, Peter A Galie, Angela Q Zhang, Jeffrey Wyckoff, Luke Whitesell, Christopher S Chen, Susan Lindquist, Sangeeta N Bhatia

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Nanotheranostics Targeting the Tumor Microenvironment.Frontiers in bioengineering and biotechnology · 2019
    Review
  9. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017
    Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Alexander F BagleyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. MD-PhD Program, Harvard Medical School, Boston, Massachusetts.
Ruth Scherz-ShouvalWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Peter A GalieDepartments of Bioengineering and Physiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Angela Q ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Jeffrey WyckoffKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Luke WhitesellWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Christopher S ChenDepartments of Bioengineering and Physiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Susan LindquistWhitehead Institute for Biomedical Research, Cambridge, Massachusetts. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. Howard Hughes Medical Institute, Cambridge, Massachusetts.
Sangeeta N BhatiaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. Howard Hughes Medical Institute, Cambridge, Massachusetts. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts. Broad Institute, Cambridge, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. sbhatia@mit.edu.
Massachusetts Institute of Technology · USUniversity of Pennsylvania · USWhitehead Institute for Biomedical Research · USBroad Institute · USHarvard University · USHoward Hughes Medical Institute · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6M
The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
Tissue Chips for Rare Disease: Adding Timothy Syndrome to the HeLIVaSkCa platformUH3EB017103 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI VUNJAK-NOVAKOVIC, GORDANA · 2014 to 2016
$7.1M
REGULATION OF ANGIOGENESIS BY MICROENVIRONMENTAL CUESR01EB000262 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHRISTOPHER S · 2002 to 2023
$6.2M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NCI NIH HHS P30-CA14051NCI NIH HHS U54 CA151884NCI NIH HHS U54CA151884NIBIB NIH HHS R01 EB000262NIBIB NIH HHS UH3 EB017103NIEHS NIH HHS P30 ES002109NIEHS NIH HHS P30-ES002109NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32GM007753
6 · The paper itself

Abstract

The delivery of diagnostic and therapeutic agents to solid tumors is limited by physical transport barriers within tumors, and such restrictions directly contribute to decreased therapeutic efficacy and the emergence of drug resistance. Nanomaterials designed to perturb the local tumor environment with precise spatiotemporal control have demonstrated potential to enhance drug delivery in preclinical models. Here, we investigated the ability of one class of heat-generating nanomaterials called plasmonic nanoantennae to enhance tumor transport in a xenograft model of ovarian cancer. We observed a temperature-dependent increase in the transport of diagnostic nanoparticles into tumors. However, a transient, reversible reduction in this enhanced transport was seen upon reexposure to heating, consistent with the development of vascular thermotolerance. Harnessing these observations, we designed an improved treatment protocol combining plasmonic nanoantennae with diffusion-limited chemotherapies. Using a microfluidic endothelial model and genetic tools to inhibit the heat-shock response, we found that the ability of thermal preconditioning to limit heat-induced cytoskeletal disruption is an important component of vascular thermotolerance. This work, therefore, highlights the clinical relevance of cellular adaptations to nanomaterials and identifies molecular pathways whose modulation could improve the exposure of tumors to therapeutic agents.

Indexed as

Adaptation, PhysiologicalHot TemperatureAnimalsAntibiotics, AntineoplasticCell Line, TumorCells, CulturedDoxorubicinDrug Delivery SystemsEndothelium, VascularFemaleHumansHyperthermia, InducedKaplan-Meier EstimateMice, Inbred NODMice, KnockoutMice, NudeAntibiotics, AntineoplasticDoxorubicin

Identifiers

PMID26122846
PMCPMC4833008
OpenAlexW2171786174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.